Complex Systems with Patrick McKenzie (patio11)
From molecule to medicine, with Ross Rheingans-Yoo
Oct 31, 2024
In this discussion, Ross Rheingans-Yoo, an expert in drug development, delves into the complexities of drug approval processes, revealing systemic inefficiencies and the evolving landscape of clinical trials. He reflects on historical events like the thalidomide crisis and how they shaped FDA policy, while also highlighting the impact of the AIDS epidemic and COVID-19 on accelerated approvals. Ross shares his innovative work in rescuing abandoned drugs and emphasizes the need for integrating technology into medicine to enhance patient care and streamline drug development.
01:28:34
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- The intricate journey of drug development starts in academic labs, requiring navigation through various approval processes before reaching patients.
- Pharmaceutical companies face significant economic pressures, necessitating drugs to generate substantial revenue during their patent life for project viability.
Deep dives
The Journey of Drug Development
Drug development typically begins in a university lab, where researchers explore the properties of molecules with potential medical benefits. When a drug advances beyond the early investigative stages, it passes through a university's tech transfer office and is spun out into a startup company that seeks venture capital funding. This company then undertakes preclinical studies in animals, followed by an Investigational New Drug (IND) application to the FDA, which must be approved before human trials can commence. This entire process, from academic research to regulatory approval, illustrates the intricate path that a new drug must navigate before reaching patients.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
